Coverage
-
May 05, 2014
A California federal judge dismissed a consolidated class action against Peregrine Pharmaceuticals Inc. for the second time on Friday, saying the suit had failed to adequately allege that the drugmaker acted recklessly by knowingly lying about its lung cancer drug.
2 other articles on this case.
View all »